Hypothesis

Sustained β‑hydroxybutyrate (BHB) levels in the 3–5 mM range, matching the IC50 for class I/IIa HDACs, will produce greater histone acetylation and downstream longevity benefits than the ~1–2 mM achieved by ketogenic diets alone, provided that exposure is intermittent to prevent p53‑dependent cellular senescence.

Rationale

• BHB inhibits HDAC1, HDAC3, and HDAC4 with IC50 values of 2.4–5.3 mM [1], yet typical ketosis peaks at 1–2 mM [2], suggesting submaximal epigenetic modulation.
• Continuous ketogenic diets extend median lifespan [3] but induce p53‑dependent senescence in heart and kidney after long term [6], indicating a trade‑off between epigenetic benefit and stress‑induced aging.
• Intermittent high‑dose BHB (e.g., ketone ester pulses) could achieve maximal HDAC inhibition during the 'on' phase while allowing clearance and recovery during the 'off' phase, limiting chronic activation of DNA‑damage sensors.

Novel Mechanistic Insight

We propose that the longevity‑promoting acetylation of FOXO3A and MT2 promoters requires a threshold of histone acetylation that is only reached when HDAC activity falls below ~30 % of baseline. This threshold corresponds to intracellular BHB ≈ 4 mM. However, prolonged HDAC inhibition disrupts NAD⁺‑dependent deacetylase SIRT1 activity and triggers a compensatory p53 rise via increased acetyl‑p53 stability, driving senescence. Pulsed high BHB would transiently dip HDAC activity below the threshold, boost acetylation, then permit SIRT1 reactivation and p53 turnover during low‑BHB intervals, thereby uncoupling the epigenetic benefit from the senescence trigger.

Experimental Design (Mouse)

1. Groups (n = 50 per sex)
   • Control: standard chow.
   • KD: 89 % kcal fat ketogenic diet (≈ 2 mM BHB).
   • KD+KE-cont: ketogenic diet plus continuous ketone ester infusion to maintain 4 mM BHB.
   • KD+KE-pulse: ketogenic diet with ketone ester bolus 2 days/week to achieve transient 4–5 mM BHB, followed by 5 days of ketosis alone.
2. Measurements
   • Lifespan and healthspan (grip strength, rotarod, memory).
   • Tissue‑specific HDAC activity, H3K9ac/H3K14ac (Western blot, ChIP).
   • FOXO3A and MT2 mRNA/protein levels.
   • Senescence markers: p16^Ink4a, p21^Cip1, SASP cytokines (IL‑6, CXCL1).
   • p53 acetylation and total levels.
   • NAD⁺/NADH ratio, SIRT1 activity.
3. Predictions
   • KD+KE-cont will show highest histone acetylation but also elevated p53‑acetyl and senescence markers in heart/kidney.
   • KD+KE-pulse will match or exceed KD in FOXO3A/MT2 upregulation, retain low senescence, and yield the greatest median and maximal lifespan extension.
   • If KD+KE-pulse fails to extend lifespan beyond KD, the hypothesis that supra‑physiological BHB via intermittent dosing adds benefit is falsified.

Human Translatability

A parallel observational cohort (≥ 1000 adults) using wearable β‑hydroxybutyrate sensors could categorize participants by average ketosis level and variability (coefficient of variation). We would test whether individuals spending ≥ 10 % of time at 3–5 mM BHB with low‑frequency spikes have lower epigenetic age clocks (e.g., GrimAge) and reduced senescence‑associated plasma phenotypes compared with steady 1–2 mM ketosis, controlling for calories and macronutrients.

Summary

By directly linking the pharmacodynamics of BHB‑mediated HDAC inhibition to the dynamics of p53‑driven senescence, this hypothesis offers a concrete, falsifiable roadmap to determine whether pushing ketone bodies into their enzymatic IC50 range—timed to avoid chronic stress—can unlock the full longevity potential observed in rodent models.